📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Wanbury Gets Brazil ANVISA Approval for Sertraline Form II and Rs 15 Cr Metformin Order
Wanbury Limited has received ANVISA approval from Brazil for Sertraline Form II, which complements its existing Form I approval. The company currently holds a dominant 75% market share for Sertraline in Brazil, and this new approval is expected to further consolidate its position. Additionally, the company secured approval from a major customer for a special Metformin DC grade, representing a potential revenue opportunity of Rs 15 crore per annum. Both manufacturing sites in Patalganga and Tanuku remain cGMP compliant, ensuring steady production capabilities.
Key Highlights
Received ANVISA (Brazil) approval for Sertraline Form II to strengthen market dominance.
Currently holds a 75% market share for Sertraline in the Brazilian market.
Secured a new Metformin DC grade approval with an estimated Rs 15 crore annual business potential.
Manufacturing facilities at Patalganga and Tanuku confirmed as cGMP compliant.
Approval for Form II is expected to further consolidate the company's share of business in Brazil.
💼 Action for Investors
Investors should note the company's strong market position in Brazil and the incremental revenue from the new Metformin order. The stock remains a positive watch for growth in the API segment and continued regulatory compliance.
Wanbury Reports Financial Turnaround: Debt Reduced by 75% and FY25 EBITDA Reaches ₹80 Cr
Wanbury Limited has successfully executed a major financial turnaround, reducing its peak debt of ₹700 crore by approximately 75% and lowering borrowing costs from 22.5% to 12.5%. The company achieved its highest-ever operational EBITDA of ₹80 crore in FY25, driven by a dominant 30% global market share in Sertraline and 11% in Metformin. The formulations business reached financial break-even in 9MFY26, with a scale-up strategy planned for FY27. Future growth is anchored by a pipeline of four new molecule commercializations annually starting in FY27, supported by a ₹127 crore CAPEX plan for FY26-27.
Key Highlights
Debt reduced by ~75% from peak levels with interest rates slashed from 22.5% to 12.5% effective March 2025.
Global market leadership established with a 30% share in Sertraline and 11% share in Metformin APIs.
Formulations segment achieved financial break-even in 9MFY26 after years of turnaround efforts.
Aggressive CAPEX plan of ₹64 Cr for FY26 and ₹63 Cr for FY27 focusing on new product blocks and clean rooms.
Operational EBITDA scaled approximately 3X between FY23 and FY25, reaching a record ₹80 crore.
💼 Action for Investors
Investors should focus on the company's transition from a debt-heavy turnaround story to a growth-oriented API player with a de-risked balance sheet. Monitor the successful launch of the new anaesthetic molecule in Q4FY26 as a litmus test for the upcoming high-frequency product launch strategy.
Wanbury Limited Announces Q3 & 9M FY26 Un-audited Financial Results
Wanbury Limited has officially released its un-audited financial results for the third quarter and nine-month period ending December 31, 2025 (FY26). The announcement was communicated via a formal press release dated February 6, 2026. This filing is a standard regulatory requirement providing transparency into the company's recent operational performance. Investors should now examine the detailed profit and loss statements to evaluate the company's growth trajectory in the pharmaceutical sector.
Key Highlights
Release of un-audited financial results for the quarter ended December 31, 2025.
Consolidated and standalone performance for the 9-month (9M) period of FY26 included.
Official press release issued on February 6, 2026, to provide management context.
Compliance with SEBI Listing Obligations and Disclosure Requirements confirmed.
💼 Action for Investors
Investors should review the full financial tables for specific trends in revenue and EBITDA margins. Compare the Q3 performance against previous quarters to assess if the company is maintaining its growth momentum.
Wanbury Approves Q3 FY26 Results, Grants 60,000 ESOPs and Allots 47,400 Shares
Wanbury Limited's board met on February 5, 2026, to approve the un-audited financial results for the quarter ended December 31, 2025. The company announced the grant of 60,000 new stock options to employees at an exercise price of ₹130 per share. Additionally, the board approved the allotment of 47,400 equity shares following the exercise of previously vested options, generating ₹4.74 lakh in capital. As a result, the company's total paid-up share capital has increased to ₹34.94 crore.
Key Highlights
Approved un-audited financial results for the third quarter and nine months ended December 31, 2025
Granted 60,000 new stock options under ESOP 2016 at a pricing formula of 50% of the closing market price (₹130 per share)
Allotted 47,400 equity shares of face value ₹10 each to employees upon exercise of vested options
Total paid-up share capital increased from ₹34,89,19,980 to ₹34,93,93,980
Realized ₹4,74,000 in cash from the exercise of 47,400 options
💼 Action for Investors
Investors should examine the detailed Q3 financial results separately to evaluate the company's fundamental performance. The current equity dilution from ESOPs is minimal and part of standard employee retention strategies.
Wanbury Approves Q3 Results, Grants 60,000 ESOPs, and Allots 47,400 Equity Shares
Wanbury Limited's board met on February 5, 2026, to approve the un-audited financial results for the quarter and nine months ending December 31, 2025. The company announced a fresh grant of 60,000 stock options to employees at an exercise price of Rs. 130 per share. Additionally, the board allotted 47,400 equity shares following the exercise of vested options under the 2016 ESOP plan. This allotment has marginally increased the company's total paid-up share capital to Rs. 34.94 crore.
Key Highlights
Approved un-audited financial results for Q3 and the nine-month period ended December 31, 2025
Granted 60,000 new ESOPs at an exercise price of Rs. 130 per share, representing 50% of the closing market price
Allotted 47,400 equity shares of Rs. 10 each, realizing Rs. 4,74,000 from the exercise of options
Total paid-up share capital increased from Rs. 34,89,19,980 to Rs. 34,93,93,980
The total number of equity shares outstanding now stands at 3,49,39,398
💼 Action for Investors
Investors should review the detailed Q3 financial results once published to evaluate the company's fundamental performance. The current ESOP activity results in negligible equity dilution while serving as an employee retention tool.
Wanbury Achieves First Sales and Commercial Shipment of New Anaesthetic API
Wanbury Limited has successfully commenced commercial shipments of its new high-demand Anaesthetic API from its Tanuku facility in Andhra Pradesh. The first sale and invoicing milestone was achieved on January 30, 2026, for a leading European customer. This move marks the company's entry into a high-growth segment just months after the initial product launch. Management expects this to signal rapid growth and production ramp-up, strengthening its global API portfolio which already serves over 50 countries.
Key Highlights
Achieved first sales and invoicing of a new high-demand Anaesthetic API on January 30, 2026
Commenced commercial shipments to a leading European customer from the USFDA/EUGMP approved Tanuku facility
Commercialization achieved within just months of the product launch, indicating high operational efficiency
Management signals rapid growth ahead with plans to multiply production capacity and scaling fast
💼 Action for Investors
Investors should monitor the revenue contribution from this new API in upcoming quarterly results to validate the scale of the production ramp-up. The successful entry into the specialized anaesthetic segment enhances the company's margin profile and global competitiveness.
Wanbury Launches Anaesthetic API Production; Targets ₹100 Cr+ Incremental Revenue in FY27
Wanbury Limited has commenced commercial production of a high-potent anaesthetic API at its Tanuku facility in Andhra Pradesh. This move is expected to generate incremental revenues of approximately ₹18 crore in Q4 FY26 and over ₹100 crore in FY 2026-27. The company is also expanding its capacity with a multi-purpose intermediate block scheduled for completion by March 2026. This expansion aims to capture a share of the global market for these new APIs, which is currently valued at over ₹5,000 crore.
Key Highlights
Commenced commercial production of a key anaesthetic API at the state-of-the-art Tanuku facility.
Projected incremental revenue of over ₹100 crore in FY 2026-27 from the new API production.
Expected immediate revenue contribution of approximately ₹18 crore in Q4 FY 2025-26.
On track to launch four additional high-value APIs (Antidiabetic, Anticoagulant, etc.) by March 2026.
Targets a global market opportunity for these molecules valued at over ₹5,000 crore.
💼 Action for Investors
Investors should track the company's ability to scale production and meet the ₹18 crore revenue target in Q4 FY26 as a sign of execution capability. The successful launch of the additional four APIs in March 2026 could be a further re-rating trigger for the stock.
Wanbury Launches Anaesthetic API Production; Targets Rs 100 Cr+ Incremental Revenue in FY27
Wanbury Limited has commenced commercial production of a high-potent anaesthetic API at its Tanuku facility in Andhra Pradesh. The company expects this launch to generate incremental revenues of approximately Rs. 18 crore in Q4 FY26 and over Rs. 100 crore in FY 2026-27. Furthermore, a new multi-purpose production block is on track for completion by March 2026, which will facilitate the production of four additional high-value APIs. These strategic moves target a global market opportunity valued at over Rs. 5,000 crore, significantly strengthening the company's API portfolio.
Key Highlights
Commenced commercial production of a key anaesthetic API at the state-of-the-art Tanuku facility.
Projected incremental revenue of over Rs. 100 crore for FY 2026-27 and Rs. 18 crore for Q4 FY26.
Multi-purpose intermediate production block for four additional APIs expected to be ready by March 2026.
New products target high-value therapeutic categories including Anticoagulants and Antidepressants.
The global market for the upcoming pipeline of APIs is currently valued at over Rs. 5,000 crore.
💼 Action for Investors
Investors should track the timely commissioning of the multi-purpose block in March 2026 and the subsequent revenue ramp-up in the coming quarters. The projected revenue growth represents a significant expansion for the company, making it a positive development for long-term shareholders.